Showing results (121-130 of 133) with videos related to
Sort By:
Pageof 14
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.Alimentary Pharmacology & Therapeutics|June 10, 2026
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA RegistryManuel Barreiro-de Acosta, Yamile Zabana, Laura Nieto-García, et al.Journal of Clinical Medicine|July 29, 2023
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNPCristina Rubín de Célix, Javier Martín-de-Carpi, Gemma Pujol-Muncunill, et al.United European Gastroenterology Journal|December 6, 2025
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA RegistryMíriam Mañosa, Margalida Calafat, Elena Ricart, et al.Journal of Crohn'S & Colitis|April 16, 2021
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA RegistryMaría Chaparro, Ana Garre, Marisa Iborra, et al.Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.Alimentary Pharmacology & Therapeutics|June 29, 2024
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registryRocío Ferreiro-Iglesias, Sol Porto Silva, Sandra Marín, et al.Pageof 14